findmyKOL

Naveen Pemmaraju, MD

Enriched profile

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center · The University of Texas MD Anderson Cancer Center

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyInternal MedicineFocusAcute Myeloid Leukemia Research+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Naveen Pemmaraju is Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,429 publications with 23,167 citations (h-index 72); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 27 Aug 2026

Naveen Pemmaraju, M.D., is Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. The public record shows 1,429 publications with 23,167 citations (h-index 72), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 29 companies.

  • Most recent indexed publication: 2026 · Blood advances
  • Top research focus: Acute Myeloid Leukemia Research
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
MDS / MPN4 trialsLeukemia (AML/ALL/CML/CLL)3 trialsPrimary Myelofibrosis2 trialsLeukemia, Myeloid, Acute2 trialsBlastic Plasmacytoid Dendritic Cell Neoplasm2 trialsPolycythemia Vera1 trialPolycythemia1 trialRecurrence1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials2Industry payments9Publications37Elzonrisgeneric · TagraxofuspClinical trials1Industry payments11Publications9Jakafigeneric · RuxolitinibClinical trials1Industry payments3Publications4

Works with

trial sponsors and companies reporting payments
Incyte CorporationClinical trialsIndustry payments35Abbvie Inc.Clinical trialsIndustry payments26GlaxoSmithKline, LLC.Clinical trialsIndustry payments18

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,429publications

Distinct works indexed by OpenAlex, matched via ORCID; 144 in PubMed.

23,167citations

Total citations across indexed works.

72h-index

Hirsch index (OpenAlex). i10-index 424.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    59.7%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor30.6%
    Valacyclovir100%
    Part D<11 patients
    Fluoroquinolone Antibacterial29.2%
    Levofloxacin100%
    Part D12 patients
  • Cardiovascular

    20.8%
    Statin20.8%
    Rosuvastatin Calcium100%
    Part D<11 patients
  • Cancer & immunology

    19.4%
    BCL-2 Inhibitor19.4%
    Venclexta100%
    Part D<11 patients
Where care is delivered (Part B)98% facility · 2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/naveen-pemmaraju-md-a670496b

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Naveen-Pemmaraju-2

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • X / Twitter

    x.com/doctorpemm

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    themedicinementors.libsyn.com/the-story-behind-the-story-with-dr-naveen-pemmaraju

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →themedicinementors.libsyn.com
  • Other

    mdanderson.org/cancerwise/leukemia-specialists--how-advances-in-measurable-residual-disease-MRD-are-improving-treatment.h00-159779601.html

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Hematology

    2012
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    Medical Oncology

    2011
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Hematology/Oncology fellowship

    MD Anderson Cancer Center

    2011
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Board Certified

    American Board of Internal Medicine

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Internal Medicine residency

    Johns Hopkins University, Osler Medical Program

    2008
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • M.D.

    University of Arkansas for Medical Sciences

    2005
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org

Editorial & leadership roles

journal and society appointments
  • Member

    Cancer Communications Committee, American Society of Clinical Oncology

    2029
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Contributing Editor

    The Hematologist

    2028
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
  • Co-Chair

    Emil J Freireich Leukemia Hematology Grand Rounds

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org
5 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Co-Section Head

    MPNs, Clinical Research Center for Myeloproliferative Neoplasms, MD Anderson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.